002675SZSE
🚨 Material Event

Announcement on Re-submission of Application for H-Share Listing by Yantai Blue-Nac Biotechnology Co., Ltd. to the Hong Kong Stock Exchange and Publication of Application Materials

✨ AI Summary

Yantai Dongcheng Pharmaceutical Group is proceeding with the spin-off and listing of its subsidiary, Yantai Blue-Nac Biotechnology, on the Hong Kong Stock Exchange. Blue-Nac re-submitted its IPO application on June 12, 2026. The announcement provides a link to the application materials for domestic investors. The listing is subject to regulatory approvals.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Stock Code: 002675 Stock Abbreviation: Dongcheng Pharmaceutical Announcement No.: 2026-044

Yantai Dongcheng Pharmaceutical Group Co., Ltd. Announcement on Re-submission of Application for H-Share Listing by Subsidiary Yantai Blue-Nac Biotechnology Co., Ltd. to the Hong Kong Stock Exchange and Publication of Application Materials

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed herein, and that there are no false records, misleading statements, or material omissions.

Yantai Dongcheng Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Dongcheng Pharmaceutical" or the "Company") is currently undertaking the spin-off of its subsidiary, Yantai Blue-Nac Biotechnology Co., Ltd. (hereinafter referred to as "Blue-Nac"), for listing on the Main Board of The Stock Exchange of Hong Kong Limited (hereinafter referred to as the "Hong Kong Stock Exchange") (hereinafter referred to as the "Spin-off").

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.